News & Media
-
5/15/2024
Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer Opens a new window
New England Journal of Medicine
-
10/21/2023
ESMO: Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer
MD Anderson Cancer Center News Release
-
5/30/2023
In New ‘Cool 100,’ Mag Counts Down Houston’s Top Movers, Shakers and Makers Opens a new window
Houston City Book
-
5/5/2022
Annual Meeting 2022: The New Frontier of Immunotherapy in Lung Cancer - Boosting the Immune Response Before Surgery. Opens a new window
Cancer Research Catalyst, The Official Blog of the American Association for Cancer Research
-
4/12/2022
Boosting Responses to Neoadjuvant Therapy in Resectable NSCLC Opens a new window
MedPage Today
-
4/12/2022
New Findings From the NeoCOAST Trial on Durvalumab-Based Therapy Opens a new window
ASCO Post Interview
-
4/11/2022
AACR: Combination immunotherapy treatment effective before lung cancer surgery
MD Anderson Cancer Center News Release
-
8/25/2021
Neoadjuvant immunotherapy can produce nodal immune flair in lung cancer. -- Cascone T and Sepesi B. Opens a new window
Newswise. MD Anderson Research Highlights for August 25, 2021.
-
6/20/2021
Combo Immunotherapy Improves Outcomes for Early-Stage NSCLC Opens a new window
Oncology Times, Volume:43 Number 12, page 1,11 – 11
-
3/9/2021
Phase II randomised study met prespecified primary endpoint threshold in patients with operable non-small cell lung cancer Opens a new window
ESMO Oncology News
-
2/18/2021
Study reveals promising, less toxic treatments for patients with lung cancer. Opens a new window
Conquer Cancer. The ASCO Foundation News.
-
2/18/2021
Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer -- Cascone T and Sepesi B.
MD Anderson Cancer Center News Release
-
11/20/2020
MD Anderson researchers present immunotherapy advances at Society for Immunotherapy of Cancer Annual Meeting. Highlights include positive clinical data from combination therapies in patients with melanoma and lung cancer - Cascone T and Sepesi B.
MD Anderson Newsroom
-
11/27/2019
Remaining Challenges With Perioperative Immunotherapy in NSCLC. Opens a new window
OncLive Interview
-
6/2019
Toxicity Of Nivolumab and Ipilimumab: We're Still Learning How To Leverage These Treatments In The Pre-Operative Setting Opens a new window
OncologyTube Interview
-
6/11/2019
Nivo/ipi shrinks early NSCLC before surgery Opens a new window
MedEdge Conference Coverage
-
6/06/2019
Combination Checkpoint Blockade for Early-Stage Non–Small-Cell Lung Cancer Opens a new window
Cancer Network Interview
-
6/2/2019
Neoadjuvant Nivolumab/Ipilimumab Shows Promise in Resectable NSCLC Opens a new window
ASCO Daily News
-
6/1/2019
ASCO 2019: Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers Opens a new window
ecancer
-
6/1/2019
Clinical and translational results from the NEOSTAR study: Treating early-stage lung cancer with nivolumab plus ipilimumab Opens a new window
ecancer Interview
-
8/5/2018
Priming Immune System Prior to Surgery May Improve Outcomes Opens a new window
Oncology Times, August 5, 2018 - Volume 40 - Issue 15 - p 22,31.
-
7/26/2016
Spotlight: What I Do As A Cancer Researcher Opens a new window
Lifehacker